Biodegradable Tocopherol Eye Drop Formulations for Sustained Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current topical eye drop formulations provide only short-term exposure to beneficial agents, often requiring frequent administration and can cause irritation, and may result in systemic side effects due to high blood concentrations and instability, necessitating a more efficient and economical method for sustained drug delivery.
Innovation Solution
Development of biocompatible, biodegradable sustained-release formulations using tocopherol isomers, tocotrienols, and omega-3 fatty acids for extended release of active agents over four days or more, suitable for topical administration to the eye, including combinations with steroids and antioxidants to minimize side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional topical eye drop formulations are used, then the administration is simple and economical, but the duration of action is short and frequent administration is required
Solution Approach 1:
The patent changes the physical and chemical parameters of the excipient materials used in eye drop formulations. Specifically, it employs biodegradable polymers with controlled molecular weights, compositions, and degradation rates to extend drug release from conventional short-term to sustained release over days to weeks, directly resolving the contradiction between duration of action and ease of administration
Solution Approach 2:
The patent utilizes composite material systems consisting of biodegradable polymer excipients combined with therapeutic agents. These composite formulations enable sustained drug delivery while maintaining ease of administration as eye drops, eliminating the need for complex implantable devices or frequent dosing
2Reliability
If high doses of medications are administered to achieve therapeutic efficacy, then the therapeutic effect is improved, but toxic side effects increase
Solution Approach 1:
The patent applies local quality by designing formulations that concentrate therapeutic agents at the target site (eye) through sustained local release from biodegradable excipients. This localized sustained delivery achieves reliable therapeutic efficacy while minimizing systemic absorption and associated toxic side effects, directly addressing the contradiction between therapeutic efficacy and toxicity
3Reliability
If frequent administration is required to maintain therapeutic levels, then the therapeutic efficacy is maintained, but the loss of time and patient compliance worsen
Solution Approach 1:
The patent implements continuity of useful action through sustained-release formulations that maintain therapeutic drug levels continuously over extended periods (days to weeks) using biodegradable polymer excipients. This continuous local delivery at the eye site eliminates the need for frequent administrations, reducing time loss and improving patient compliance while maintaining reliable therapeutic efficacy
4Stability of the object's composition
If standard eye drop formulations are used, then the manufacturing is simple, but the stability over treatment period is poor
Solution Approach 1:
The patent changes the compositional parameters of eye drop formulations by incorporating biodegradable polymer excipients with specific molecular weights, compositions, and degradation characteristics. These parameter changes enhance formulation stability over the treatment period while maintaining manufacturability through conventional eye drop preparation methods, resolving the contradiction between stability and ease of manufacture
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations deliver therapeutic levels of active agents over an extended period, reducing the need for frequent administration and minimizing systemic side effects, while maintaining non-toxicity and biocompatibility, effectively addressing the limitations of existing eye drop formulations.
Implementation Method 1
biocompatible, biodegradable excipient that sustains the release of the active agent
Implementation Method 2
deliver therapeutic and non-toxic levels of active agents over the desired extended time frame
Implementation Method 3
The active agent or excipient may be an omega-3 fatty acid or an ester thereof
Implementation Method 4
The formulations deliver therapeutic levels of active agents over an extended period, reducing the need for frequent administration and minimizing systemic side effects, while maintaining non-toxicity and biocompatibility
Data Source
AI summary
This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably α-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents.